

Thank you for your interest in ruling out Fabry disease in patients who may be at risk. Did you know...

- Patients with Fabry disease often wait over **13 years from symptom onset to diagnosis**?[1]
- During this time, patients can experience **irreversible organ damage**

If you suspect your patient has Fabry disease:

- Order a free screening test at www.dbskit.ca and/or
- Refer to your local metabolic/genetics clinic or treatment centre

Press play to view
Fabry Disease and the Heart presented by
Gavin Y. Oudit, MD, PhD, FRCPC
Professor & Clinician-Scientist, U of Alberta
Canada Research Chair in Heart Failure

Order dry blood spot kits at www.dbskit.ca

Fabry disease is a chronic, multisystemic, progressive x-linked disease affecting both men & women

Clinical presentation is heterogeneous and organ involvement can range from multiple organ manifestations to an isolated organ being affected; however, **at least 65% of patients have cardiac involvement**[1]

& LVH
is a common manifestation

Since cardiac disease is the leading cause of death in Fabry disease and **studies have estimated 3-12% of patients with unexplained LVH have Fabry disease**[2,5,6], **Fabry disease should be considered** in patients with unexplained LVH of >12mm (males) or 11mm (females)[7,8-11], especially if they have:

- Family history of ESRD by the age of 50, or stroke, heart failure or sudden cardiac death by the age of 60[7] *OR*
- One or more of the following:

Other cardiac signs & symptoms*
Stroke/TIAs[12]
Reduced eGFR or proteinuria[7]
Neuropathic pain[7,10]

*Arrhythmias, angina, valvular abnormalities, dyspnea

CARDIOMYOPATHY IN FEMALE PATIENTS

Female patients can develop fibrosis without hypertrophy[13]

- 50% with cardiomyopathy would not have been detected by echocardiographs and LVH assessments
- When LVM was examined in CMR, LE was detected in 23% of the female patients without hypertrophy, whereas LE was never seen in male patients with normal LVM

For more information about Fabry disease and the heart:

- Click here to view our PDF guide
- Click here to access a **Section 3 accredited program** entitled *"Inherited, But Not Rare! – A Closer Look at Genetic and Treatable Cardiomyopathies"*
- Click here and enter password RMD2021 to access recorded webinars on Fabry disease, including the full version of HEART DISEASE IN PATIENTS WITH FABRY DISEASE, and to register for future learning events

Questions about Fabry disease or Takeda's screening initiatives?

Contact us!

CMR, cardiac magnetic resonance; LE, late enhancement; LVH, left ventricular hypertrophy; LVM, left ventricular mass

References
1. Mehta et al. *Eur J Clin Invest*. 2004 Mar;34(3):236-42. **2.** Spada M et al. Am J Hum Genet. 2006;79:31–40. **3.** Laney DA & Fernhoff PM. J Genet Couns. 2008;17:79–83. **4.** Linhart A et al. Eur Heart J. 2007;28:1228–1235. **5.** Nakao S et al. N Engl J Med. 1995;333:288–293. **6.** Sachdev B et al. Circulation. 2002;105:1407–1411. **7.** Yousef Z et al. Eur Heart J. 2013;34:802–808. **8.** Elliott PM et al. Eur Heart J. 2014;35:2733–2779. **9.** Germain DP. Orphanet J Rare Dis. 2010;5:30. **10.** Sirrs S et al. Canadian Fabry Disease Treatment Guidelines 2017. **11.** Linthorst GE et al. Neth Heart J. 2006;14:100–105. **12.** Golomb MR. Strokes in neonatals and children. In: Biller J. (ed). Stroke in children and young adults. Saunders Elsevier. Philadelphia, PA. 2009. p.69–80. **13.** Niemann M, *et al. JACC Cardiovasc Imaging*. 2011;4:592-601

This communication is intended for health care professionals.

VV-MEDMAT-45035 May 2021